2.65438 On February 7, 2020, Kexing Holding Biotechnology Co., Ltd. said that its subsidiary, Beijing Kexing Zhongwei Biotechnology Co., Ltd. (referred to as "Kexing Zhongwei"), obtained more than 500 million US dollars for further research and development, capacity expansion and production of novel coronavirus inactivated vaccine Kelaifu, as well as other development and operation activities of Kexing Zhongwei. It is understood that Beijing Kexing Zhongwei Biotechnology Co., Ltd. was incorporated in Beijing Administration for Industry and Commerce on May 7, 2009. The company's business scope includes the research and development of biological vaccine technology; Diagnostic kit technology, providing technical services, etc.
3. On September 8, 2020, the collective was awarded the honorary title of "National Advanced Collective in Fighting COVID-19 Epidemic" by the Central Committee, the State Council and the Central Military Commission.